Therapeutic Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene
Company Expands Use of Commercially Available Anti-Inflammatory Nanoparticle Nutraceutical NanoStilbene™ into Anti-Aging Market
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy
Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer
Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
Recent Data Supports Investigation of Commercially Available Product as an Adjuvant to Chemotherapy for Cancer
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA
Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach
Therapeutic Solutions International Continues to Refine NanoStilbene Formulation
NanoStilbene Shown to Reduce Tumor Necrosis Factor-α (TNF-α )in Cancer Patients
Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
Patent for Prevention and Reversion of CTE using “Educated”
Monocytes and Progenitor Cells
NanoStilbene Enhances Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through
Modulation of Inflammatory Mediators
Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE
Therapeutic Solutions International Signs Agreement for Licensing JadiCell’s Universal Donor Adult Stem Cell Product for Chronic Traumatic Encephalopathy and Traumatic Brain Injury
Company intends to use Stem Cells under new Right to Try law for CTE
Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio
New Data Demonstrates Ability of Immune System to Alter Football
Related Brain Injuries
Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy
Company Files Patent and Generates Proof of Concept Data using NeuroStilbene for Prevention of Football Associated Brain Damage
Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients
Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA
under President Donald Trump’s Right to Try Law
Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries
TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline
Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Company Expands Product Pipeline in Neurodegenerative Arena
Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development
Company Focuses on Non-Toxic Therapies Using Immune System to Selectively Kill Cancer Cells through Immunotherapy
Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Initiate Investigational Cardiovascular Study with Dr. Azimi and NanoStilbene
Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene
Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene
Patented Augmenter of Cancer Immunotherapy Successfully Manufactured
Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board
Dr. James Veltmeyer to Assist Company in Expansion of Clinical Applications of Pterostilbene Based Therapeutics
StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein based vaccines.
Nutraceutical Products – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.
NanoStilbene™ is a nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 200mg/ml.